Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
2002
Incidence and survival in non-hereditary amyloidosis in Sweden
2012
The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro
2001
Recent advances in the management of AL Amyloidosis
2015
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
Mechanisms of type-I- and type-II-interferon-mediated signalling
2005 Standout
MYC on the Path to Cancer
2012 Standout
The Systemic Amyloidoses
1997 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
2002
Signal integration by JNK and p38 MAPK pathways in cancer development
2009 Standout
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies
1995
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
NF-κB in cancer: from innocent bystander to major culprit
2002 Standout
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Role of AID in Tumorigenesis
2007 StandoutNobel
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma
2002
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
The development of androgen-independent prostate cancer
2001 Standout
Multiple Myeloma
2001
Cyclins and oncogenesis
1993
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Putting tumours in context
2001 Standout
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
2009
The biological and clinical significance of the KI‐67 growth fraction in multiple myeloma
1992
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Detection of minimal residual disease
2001
STATs in oncogenesis
2000 Standout
Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders
2004
Immunity, Inflammation, and Cancer
2010 Standout
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
2003
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
Genetic events in the pathogenesis of multiple myeloma
2007
Systemic amyloidosis
2015 Standout
Angiogenesis in B Cell Lymphoproliferative Diseases. Biological and Clinical Studies
1995
Infiltrative Cardiovascular Diseases
2010
High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma
1991
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Mechanisms of B-cell lymphoma pathogenesis
2005
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
1997
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
2016 Standout
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Multiple myeloma: evolving genetic events and host interactions
2002
Applications of machine learning in drug discovery and development
2019 Standout
Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis
1990
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Mechanisms of Bone Metastasis
2004 Standout
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
Evaluation and Management of the Cardiac Amyloidosis
2007
Restrictive Cardiomyopathy
1997
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
2007
Cancer as an evolutionary and ecological process
2006 Standout
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
1997
The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies
2004
Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal Gammopathies
1987
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
1993 StandoutNature
Slaying RAS with a synthetic lethal weapon
2010 StandoutNobel
Molecular Mechanisms of Amyloidosis
2003 Standout
Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44
1995
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
1998
Protein Misfolding, Functional Amyloid, and Human Disease
2006 Standout
Lymphocytic progenitor cell origin and clonal evolution of human B- lineage acute lymphoblastic leukemia
1996
Amyloidosis of the AL type
1979
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies
1994
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
2006
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
2011
Phenotypic difference of normal plasma cells from mature myeloma cells
1993
Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells
1997
Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
1995
Normal and abnormal aspects of proteinuria
1986
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases
2012 Standout
Current Trends in Diagnosis and Management of Cardiac Amyloidosis
2013
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
1999
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
2004
Magnetic Resonance Imaging of the Bone Marrow in Hematologic Malignancies
1997
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'- iodo-4'-deoxydoxorubicin
1995
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
2004
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
1998
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Amyloid Deposits and Amyloidosis
1980 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
2013
Multiple Myeloma
2010
Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosis–Associated Renal Disease
2001
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
1999
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden
2001
Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants
1999
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
1997
Autologous stem cell transplantation for primary systemic amyloidosis
2002
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
2010
Interleukin-6–Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway
1998
Genetics and Cytogenetics of Multiple Myeloma
2004
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Transthyretin (TTR) Cardiac Amyloidosis
2012
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Advances in biology of multiple myeloma: clinical applications
2004
Systemic amyloidosis: novel therapies and role of biomarkers
2016
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
2000
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
2009
Use and Abuse of RNAi to Study Mammalian Gene Function
2012 StandoutScienceNobel
Multiple Myeloma
2011 Standout
Map kinase signaling pathways and hematologic malignancies
2003
Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection
1998
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Systemic Amyloidosis in E ngland: an epidemiological study
2013
Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
1998
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
International Staging System for Multiple Myeloma
2005 Standout
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
2006
Works of RA Kyle being referenced
The spectrum of IgM mono-clonal gammopathy in 430 cases.
1987
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)
2000
Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
1999
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
1996
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]
1992
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis
1985
Response rates and survival in primary systemic amyloidosis
1991
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo
1978
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
The plasma cell labeling index: a valuable tool in primary systemic amyloidosis
1989
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]
1992
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
1986
Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease
1991
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis
1985
Multiple myeloma: significance of plasmablastic subtype in morphological classification
1985
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial
1996
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
1996
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Multiple myeloma: significance of plasmablastic subtype in morphological classification
1985
Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma
1983
Response rates and survival in primary systemic amyloidosis
1991